The United States government has approved a new drug, Lenacapavir, for preventing HIV. The drug will be sold under the name Yeztugo and will be taken just twice a year.
The U.S. Food and Drug Administration (FDA) approved the medicine after successful clinical trials showed it provides strong protection against HIV.
“This is a medicine that only needs to be given twice a year and has shown remarkable outcomes in clinical studies, which means it could transform HIV prevention,” said Daniel O’Day, Chairman and CEO of Gilead Sciences, the company that makes the drug.
O’Day called the approval “one of the most significant scientific achievements” by Gilead.
The drug is expected to help people who have trouble taking HIV prevention pills daily. It offers a more convenient option that may reduce the number of HIV infections around the world.
Also Read:
- Paediatricians Warn Parents Not to Use Perfumes on Babies
- Bacteria Causes Ulcer, Not Skipping Meals, Says Doctor
The World Health Organization (WHO) also welcomed the news, describing it as a “milestone” in the fight against HIV. WHO already recommends other HIV prevention methods like daily pills, a vaginal ring, and a long-acting injection called cabotegravir.
Meg Doherty, Director of WHO’s Global HIV, Hepatitis and STI Programmes, said the new drug could help people who face challenges taking daily medicine or visiting the clinic often.
“WHO is working with partners and national authorities to ensure Lenacapavir reaches people who need it most – quickly, safely and equitably,” she said.
Lenacapavir’s approval marks a major step forward in making HIV prevention easier, more private, and more effective.